Realizing our “Triple-A Mandate”
Four years ago, TB Alliance secured the first regulatory approval from the United States Food and Drug Administration (US FDA)
Access News
TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan
NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license
Pretomanid’s Addition to the WHO’s Essential Medicine List Enhances Access to All Oral, Six-Month DR-TB Therapy
“The addition of pretomanid to the Essential Medicines List (EML) of the World Health Organization (WHO) is a critical step
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
TB Alliance Statement on New World Health Organization Rapid Communication on Key Changes to the Treatment of Drug-Resistant Tuberculosis
New Guidelines Have Potential to Transform the TB Treatment Landscape with Six-Month Standard PRETORIA (3 May 2022)—TB Alliance applauds today’s
TB Alliance Welcomes New Data on BPaL-Based Regimens Presented at the 2021 Union Conference
New results from operational research in Ukraine and MSF’s TB-PRACTECAL study on drug-resistant forms of tuberculosis to be presented PRETORIA
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug NEW YORK and
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
New Clinical Access Program to Expand Access to Tuberculosis Treatment Pretoria, 10 December 2020—TB Alliance welcomes the Wits Health Consortium
TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder
One Year Since U.S. Approval, Accelerating Access to New TB Therapy
PRETORIA — Today marks the one year anniversary of the US FDA’s approval of pretomanid as part of the BPaL